Drastic initial response and subsequent response to two ALK inhibitors in a patient with a highly aggressive ALK-rearranged inflammatory myofibroblastic tumor arising in the pleural cavity  by Ono, Akira et al.
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A  57-year-old  male current  smoker  was  diagnosed  with  an  aggressive  variant  of  ALK-rearranged  inﬂam-
matory myoﬁbroblastic  tumor  (IMT)  arising  in  the  pleural  cavity.  First  line  treatment  with  ASP3026 was
initiated  at  a dose  of  125  mg  once  daily.  A follow-up  CT  scan  revealed  drastic  regression  of the pleural
lesion.  After  disease  progression  with  ASP3026  treatment,  LDK378  (ceritinib)  was  initiated  at  a  dose  of
750 mg  once  daily.  A follow-up  CT  scan revealed  a  second  drastic  regression  of  the  pleural lesion.  Further-nﬂammatory myoﬁbroblastic tumor
LK
SP3026
eritinib
F1
yaluronan
more,  it  is  noteworthy  that this  case  represents  the use  of serum  hyaluronan  levels  to  assist  in monitoring
of  treatment  efﬁcacy  in  an  IMT.
Herein,  we present  the  ﬁrst  case  of a  patient  with  a highly  aggressive  ALK-rearranged  IMT  arising  in
the  pleural  cavity,  who  showed  both  initial  and  subsequent  drastic  response  to two  ALK  inhibitors  while
being  monitored  for  serum  hyaluronan.
© 2016  The  Author(s).  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC. Background
ALK rearrangement is known to occur in various carcino-
as, including anaplastic large-cell lymphoma, diffuse large-cell
ymphoma, non-small cell lung cancer (NSCLC), inﬂammatory
yoﬁbroblastic tumors (IMT) and renal medullary carcinoma [1].
t has been proposed that tumors carrying abnormal ALK as the
ssential growth driver be termed collectively as“ALKoma” [2].
LK rearrangement has been documented in approximately 50% of
MTs. IMTs can occur in the mesentery, omentum, retroperitoneum,
elvis, genitourinary tract, mediastinum, spleen, liver, or GI tract
3]. Surgical resection is the only effective treatment for IMTs. No
tandard treatment for advanced IMTs has yet been established.
erein, we present a case of a patient with a highly aggressive
∗ Corresponding author at: Division of Thoracic Oncology, Shizuoka Cancer Center,
007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan.
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ttp://dx.doi.org/10.1016/j.lungcan.2016.07.002
169-5002/© 2016 The Author(s). Published by Elsevier Ireland Ltd. This is an open acces
c-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ALK-rearranged IMT  arising in the pleural cavity, who showed both
initial and subsequent response to two ALK inhibitors.
2. Case
A 57-year-old male current smoker was diagnosed as having an
aggressive variant of IMT  harboring a RANBP2-ALK rearrangement
based on the results of both a highly sensitive immunohisto-
chemical analysis and a ﬂuorescent in situ hybridization analysis
[4]. Subsequently, the RANBP2-ALK rearrangement was conﬁrmed
using real-time polymerase chain reaction (RT-PCR) (Supplemen-
tary Fig. 1). Chest CT revealed mediastinal shift to the left side
associated with a right intrapleural lesion of heterogeneous density
containing a necrotic focus, chest wall invasion, mediastinal lymph
node metastasis (#4R), and pleural dissemination (Fig. 1A). Curative
resection was  not indicated due to insufﬁcient pulmonary reserve.
Therefore, the patient was  enrolled in a phase I study of ASP 3026
being conducted in patients with advanced solid tumors. Treat-
ment with ASP3026 was initiated at a dose of 125 mg once daily
s article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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ASP3026 treatment (B), before Ceritinib treatment (C), after Ceritinib treatment (D).
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fFig. 1. Chest computed tomography scan before ASP3026 treatment (A), after 
n 14 February, 2012. The cough and exertional dyspnea rapidly
mproved. A follow-up CT scan on 11 April, 2012, revealed dras-
ic regression of the right intrapleural lesion, and the treatment
esponse was conﬁrmed as “partial response” according to RECIST
.1 criteria (Fig. 1B). However, the patient was found to show
isease progression on 26 September, 2012. A chest CT revealed
egrowth of the primary lesion, pleural dissemination, a tumor
hrombus in the superior vena cava (Fig. 1C). After disease pro-
ression with ASP3026 treatment, the patient was enrolled in the
hase I, Multicenter, Open-label Dose Escalation Study of LDK378
dministered Orally in Japanese Patients with Tumors Character-
zed by Genetic Alterations of ALK. LDK378 (ceritinib, Zykadia;
ovartis Pharmaceuticals, Basel, Switzerland) treatment (750 mg
nce daily) was initiated on 1 November, 2012. A follow-up CT on
9 May, 2013, conﬁrmed partial response according to RECIST 1.1
riteria (Fig. 1D). However, he was diagnosed as showing disease
rogression on 2 October, 2013.
At the time of initial diagnosis, the serum and pleural ﬂuid lev-
ls of hyaluronan were markedly elevated at 416,000 ng ml−1 and
59,000 ng ml−1, respectively. However, there was  no evidence of
ny pre-existing hepatic disorder. We  considered the initial clini-
al diagnosis to be malignant pleural mesothelioma. Accordingly,
e performed a thoracoscopic tumor biopsy to enable an accurate
iagnosis. It is noteworthy that serum hyaluronan was observed
s a surrogate marker correlated with changes in the tumor bur-
en (Fig. 2). The biopsy specimen was subsequently processed for
yaluronan using Alcian blue stain (ph 2.5) (Fig. 3A) and hyaluro-
an binding protein (HABP) (Fig. 3B). The cells that stained positive
or HABP, and the stroma that stained positive for alcian blue (phFig. 2. Longitudinal course of serum hyaluronan during treatment for IMT.
2.5) strongly suggested that hyaluronan was being secreted from
the IMT. We  performed two  biopsies: one at the time of diagnosis,
and after ceritinib therapy. We  assessed 24 mutation statuses in 10
genes (EGFR, KRAS, BRAF, PIK3CA, NRAS, MEK1, AKT1, PTEN, HER2,
and DDR2), as well as EML4-ALK and ROS1 translocations using
pyrosequencing plus capillary electrophoresis and RT-PCR for tis-
sue samples obtained at the time of diagnosis. Furthermore, we
assessed the presence of somatic mutations using amplicon-based
massively parallel sequencing for a tissue biopsy sample obtained
after ceritinib therapy. We  could not analyze a specimen obtained
at the time of diagnosis using amplicon-based massively parallel
A. Ono et al. / Lung Cancer 99 (2016) 151–154 153
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eFig. 3. Biopsy specimens of IMT  from the patient stained with Alcia
equencing because the amount of archived material was insufﬁ-
ient. We  did not detect any other mutations or fusion genes in the
issue sample taken at the time of diagnosis. Meanwhile, we  were
ble to detect the NF1 mutations using amplicon-based massively
arallel sequencing, but not using Sanger sequencing (Supplemen-
ary Figs. 2A, B). One of the reasons for this discrepancy may  be the
ifference in sensitivities between the two methods. In addition,
e did not detect other ALK mutations using amplicon-based mas-
ively parallel sequencing. The patient agreed to participate in an
xploratory biomarker study for thoracic malignancies at our insti-
ution. The study was conducted with the approval of the Shizuoka
ancer Center Institutional Review Board #1 (HHS IRB registration
umber; IRB00006744).
After LDK378 treatment, the following chemotherapies were
dministered: crizotinib therapy as third-line treatment (between
0 November and 9 December, 2013), and four cycles of cis-
latin + pemetrexed as fourth-line treatment (between 15 January
nd 2 April, 2014). Neither treatment led to tumor response. After
he fourth-line therapy, the patient received palliative radiation for
horacic pain due to chest wall invasion by the primary lesion and
hole-brain radiotherapy for symptomatic multiple brain metas-
ases. On 24 June, 2014, he died of IMT  under a “do-not-resuscitate”
rder.
. Discussion
Several case reports have been published on the efﬁcacy of
rizotinib therapy in patients with IMT  occurring in the omen-
um, pelvis, and abdomen [5–7]. Our report is the ﬁrst case of a
rimary ALK-rearranged IMT  arising in the pleural cavity showing
 drastic response to two ALK inhibitors, ASP3026 and ceritinib.
owever, crizotinib therapy as third-line treatment was  not effec-
ive. ASP3026 is a novel and selective small-molecule tyrosine
inase inhibitor of ALK, ROS1, and ACK kinases [8]. Ceritinib is an
rally active, small-molecule, ATP-competitive, second-generation
LK tyrosine kinase inhibitor, which received US Food and Drug
dministration (FDA) approval for the treatment of patients with
LK-positive metastatic NSCLC who show progression on or are
ntolerant to crizotinib treatment [9]. The overall response rates
ORR) to ceritinib therapy in patients who had previously received
rizotinib in a Japanese phase I and Global phase I study were 54%
nd 56%, respectively [10,11]. The activity of ceritinib in patients
hose tumors had progressed during crizotinib treatment may  be
ndependent of the underlying mechanism of acquired resistance
10]. Furthermore, sequential treatment with crizotinib and ceri-
inib yielded incremental survival outcome beneﬁts [12]. There are
everal possible mechanism capable of explaining why ceritinib
orked after ASP3026 in this case. The ﬁrst concerns the differ-
nce in the half maximal inhibitory concentration (IC50) of each of ph 2.5 (A; ×40), and hyaluronan binding protein (HABP) (B; ×40).
the drugs. In vitro, ceritinib and ASP3026 inhibited kinase activ-
ity with IC50 values of 0.20 nM and 3.5 nM,  respectively [11,13].
Ceritinib is approximately 15-fold more potent against ALK than
ASP3026. Furthermore, there were differences between the maxi-
mum tolerated dose (MTD) and the administered dose in ASP3026,
but not in ceritinib. In an American phase I study, the MTD  of ASP
3026 was  determined to be 525 mg  once daily [14], 400 mg  more
than the administered dose in this case. While the MTD  of ceri-
tinib was  found to be 750 mg  once daily in both Japanese and global
phase I studies, the same as the administered dose. Secondary resis-
tance to ALK inhibitors can be classiﬁed into ALK dominant and
ALK non-dominant [15]. Ceritinib has been shown in vitro to be
capable of overcoming the common secondary acquired L1196M
gatekeeper mutation that confers crizotinib resistance [16]. Sec-
ond, a ceritinib-sensitive ALK dominant secondary resistance might
have been present. However, we  did not perform a post-ASP3026
biopsy, and we  did not detect ALK dominant secondary mutations
using amplicon-based massively parallel sequencing in a post-
ceritinib tissue samples.
There is a poor understanding of early progression on third-line
crizotinib therapy. NF1 is a tumor suppressor gene which encodes a
RAS GTPase-activating protein (RAS GAP) known as neuroﬁbromin.
Accordingly, NF1 mutations trigger the activation of RAS and its
downstream effector pathways [17]. Loss of NF1 and reduced NF1
expression have been shown to confer resistance to EGFR and BRAF
inhibitors [17,18]. It suggests that mutated NF1 regulation of activa-
tion of bypass ALK/RAS/ERK signaling pathway might be associated
with ALK non-dominant resistance to ALK inhibitor [19].
The present report has several limitations. First, we  could not
analyze the specimen obtained at the time of diagnosis using
amplicon-based massively parallel sequencing. Second, the NF1
K478T mutation observed in the re-biopsy sample after resistance
to ceritinib was a single nucleotide variant (SNV) of unknown func-
tion. Therefore, we plan to evaluate the effect of this SNV on the
function of NF1 and the efﬁcacy of ALK inhibitors in patients with
ALK-rearranged non-small cell lung cancer in the future using data
from an exploratory biomarker study for thoracic malignancies
underway at our institution.
It is difﬁcult to conduct clinical trials because of the very low fre-
quency (0.04%) of cases with resected IMT  [20]. However treatment
of ALK inhibitors for an unapproved indication could be one option
of treatment for these patients, which is frequently conducted in
ﬁelds such as pediatrics, rare diseases, and oncology [21]. In our
case, a patient with a highly aggressive ALK-rearranged IMT  arising
in the pleural cavity showed a drastic initial response and sub-
sequent response to two  ALK inhibitors. Cytotoxic chemotherapy
cannot be expected to show efﬁcacy against advanced IMTs. ALK
inhibitors may  be effective agents for patients with advanced ALK-
rearranged IMTs regardless of the location of the primary lesion.
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